Clinical Trial Modernization Act
- Bill Number
- H.R. 3521
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-05-20: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Last Updated
- 2026-05-21T19:45:36Z
AI-Generated Summary
Purpose of the Legislation
The Clinical Trial Modernization Act aims to update and improve clinical trials for drugs, devices, and vaccines by removing financial and logistical barriers to participation. It focuses on increasing enrollment from underrepresented populations—groups such as racial or ethnic minorities, low-income individuals, rural residents, or others disproportionately affected by certain diseases, as defined by the National Institutes of Health (NIH) and Food and Drug Administration (FDA)—to ensure more diverse and inclusive research outcomes.
Key Provisions
- Grants for Outreach and Recruitment (Section 3): The Secretary of Health and Human Services (HHS) can award grants or contracts to organizations for community education, outreach, and training to boost clinical trial participation among underrepresented populations. Activities include partnering with community health centers, training healthcare workers (especially from underrepresented groups) to serve as trial investigators, engaging local stakeholders, and developing multilingual materials. Priority goes to efforts in rural or tribal areas. Funding is authorized for fiscal years 2025 and 2026.
- Safe Harbor for Participant Expenses and Digital Tools (Section 4): Amends the Social Security Act's Anti-Kickback Statute (which prohibits improper financial incentives in healthcare) to allow trial sponsors to provide payments for participant expenses (e.g., travel, meals, transportation, excluding standard patient cost-sharing like deductibles) and free digital health technologies (e.g., apps or devices for remote monitoring). These must be available to all participants and aimed at including diverse groups, including rural communities.
- Support for Covering Cost-Sharing (Section 5): Permits drug or device manufacturers to pay participants' cost-sharing obligations (e.g., copays under Medicare or Medicaid) without violating anti-kickback laws, the Civil Monetary Penalties Law, or the False Claims Act (which prevents fraudulent billing to the government). Requirements include ensuring compliance with federal coverage rules, capping enrollment, using written agreements with investigators, limiting advertising of subsidies, and stopping payments if a participant leaves the trial. Payments must not exceed actual costs or tie to future product purchases.
- Tax Exclusion for Participant Payments (Section 6): Adds a new section to the Internal Revenue Code excluding up to $2,000 per year of remuneration (e.g., expense reimbursements) from an individual's gross income for participating in approved clinical trials. This applies to trials meeting federal standards.
- Preservation of Existing Protections (Section 7): Clarifies that the bill does not limit other legal safe harbors or guidance that encourage trial participation.
Significant Changes to Existing Law
- Anti-Kickback and Penalties Laws: Expands exceptions in the Social Security Act (Sections 1128A and 1128B) to explicitly permit expense reimbursements, digital tools, and cost-sharing payments in clinical trials, provided they promote diversity and follow safeguards. Previously, such payments could be seen as illegal inducements.
- Tax Code: Introduces a new exclusion (Section 139J) in the Internal Revenue Code, making trial-related payments tax-free up to a cap, which did not exist before. This reduces financial disincentives for participants.
- No Changes to Core Trial Regulations: Builds on existing FDA and NIH frameworks for diversity plans in trials (e.g., under the Federal Food, Drug, and Cosmetic Act) without altering approval processes.
Potential Impacts
- On Government Agencies: HHS, FDA, Centers for Medicare & Medicaid Services (CMS), and the IRS will need to implement grants, update regulations, and enforce new safe harbors, potentially increasing administrative oversight but also improving trial data quality. Appropriations for grants could strain budgets if not fully funded.
- On Citizens: Lowers financial barriers for trial participation, especially for underrepresented and rural groups, potentially leading to better access to experimental treatments and more equitable health research. The $2,000 tax break could save participants money, encouraging broader involvement without tax penalties.
- On International Relations: Minimal direct impact, as the bill focuses on U.S. domestic trials and federal programs like Medicare/Medicaid. However, more diverse U.S. trial data could indirectly influence global drug approval standards by providing stronger evidence for FDA decisions.
Main Stakeholders Affected
- Underrepresented Populations: Primary beneficiaries, gaining easier access to trials through outreach, expense coverage, and reduced costs, which could address health disparities.
- Clinical Trial Participants and Patients: All trial enrollees benefit from reimbursements and tax exclusions, but safeguards prevent overuse or fraud.
- Healthcare Providers and Investigators: Community sites, health centers, and trained personnel (especially from diverse backgrounds) receive support for recruitment and operations.
- Drug/Device Sponsors and Manufacturers: Gain legal clarity to offer incentives without penalty risks, facilitating faster, more diverse trials.
- Community Organizations and Unions: Eligible for grants to partner in outreach, amplifying local involvement.
- Government Entities: HHS/FDA/CMS oversee implementation; IRS handles tax provisions; Congress authorizes funding.
Notable Legal, Constitutional, or Political Implications
- Legal Implications: Creates targeted safe harbors under anti-fraud laws, reducing litigation risks for sponsors while mandating protections against abuse (e.g., enrollment caps, no advertising). This balances innovation with preventing improper inducements but may require new FDA/HHS guidance to clarify "approved" trials.
- Constitutional Implications: None directly; aligns with Congress's authority over interstate commerce and spending (e.g., via grants and tax policy) without infringing on free speech or equal protection, as it promotes inclusion without mandating participation.
- Political Implications: Bipartisan sponsorship (introduced by Reps. Ruiz and Pfluger) signals broad support for health equity. It could spur future legislation on trial diversity but faces debates over costs, enforcement, and whether incentives might skew research priorities toward certain demographics. The bill's focus on rural and tribal areas addresses ongoing equity concerns in U.S. healthcare policy.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (5)
Rep. Pfluger, August [R-TX-11], Rep. Ciscomani, Juan [R-AZ-6], Rep. Cohen, Steve [D-TN-9], Rep. Soto, Darren [D-FL-9], Rep. Auchincloss, Jake [D-MA-4]
Recent Actions
- 2025-05-20: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2025-05-20: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2025-05-20: Introduced in House
- 2025-05-20: Introduced in House
Bill Versions
- Clinical Trial Modernization Act — issued 2025-05-20 — PDF (11 pages)